San Diego, CA -- (SBWIRE) -- 01/30/2017 -- The Shareholders Foundation announced that an investor, who purchased shares of Innocoll Holdings PLC (NASDAQ:INNL), filed a lawsuit in Pennsylvania over alleged Securities Laws violations by Innocoll Holdings PLC in connection with certain allegedly false and misleading statements

Investors who purchased shares of Innocoll Holdings PLC (NASDAQ:INNL) have certain options and for certain investors are short and strict deadlines running. Deadline: March 27, 2017. NASDAQ:INNL investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The plaintiff claims that between November 3, 2016 and December 29, 2016 the Defendants made false and/or misleading statements and/or failed to disclose that Innocoll's New Drug Application ("NDA") submission to the FDA in October 2016 for XARACOLL was incomplete, that due to the incomplete NDA submission, XARACOLL would not be approved in 2017 as investors were led to believe, and that as a result, Defendants' statements about Innocoll's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

On December 29, 2016, Innocoll Holdings PLC announced that it has received a Refusal to File letter from the United States Food and Drug Administration ("FDA") for XARACOLL, the company's product candidate for the treatment of postsurgical pain.

Those who purchased shares of Innocoll Holdings PLC have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com